Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC
Errataetall: |
CommentOn: N Engl J Med. 2023 Nov 16;389(20):1839-1850. - PMID 37870973 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:390 |
---|---|
Enthalten in: |
The New England journal of medicine - 390(2024), 4 vom: 25. Jan., Seite 381 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Dingemans, Anne-Marie C [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Monoclonal, Humanized |
---|
Anmerkungen: |
Date Completed 25.01.2024 Date Revised 25.01.2024 published: Print CommentOn: N Engl J Med. 2023 Nov 16;389(20):1839-1850. - PMID 37870973 Citation Status MEDLINE |
---|
doi: |
10.1056/NEJMc2314327 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM36756078X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM36756078X | ||
003 | DE-627 | ||
005 | 20240126232154.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240124s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1056/NEJMc2314327 |2 doi | |
028 | 5 | 2 | |a pubmed24n1271.xml |
035 | |a (DE-627)NLM36756078X | ||
035 | |a (NLM)38265653 | ||
035 | |a (PII)10.1056/NEJMc2314327#sa1 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Dingemans, Anne-Marie C |e verfasserin |4 aut | |
245 | 1 | 0 | |a Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.01.2024 | ||
500 | |a Date Revised 25.01.2024 | ||
500 | |a published: Print | ||
500 | |a CommentOn: N Engl J Med. 2023 Nov 16;389(20):1839-1850. - PMID 37870973 | ||
500 | |a Citation Status MEDLINE | ||
650 | 4 | |a Letter | |
650 | 4 | |a Comment | |
650 | 7 | |a pembrolizumab |2 NLM | |
650 | 7 | |a DPT0O3T46P |2 NLM | |
650 | 7 | |a selpercatinib |2 NLM | |
650 | 7 | |a CEGM9YBNGD |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
650 | 7 | |a Pyrazoles |2 NLM | |
650 | 7 | |a Pyridines |2 NLM | |
650 | 7 | |a RET protein, human |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
650 | 7 | |a Proto-Oncogene Proteins c-ret |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
700 | 1 | |a Smit, Egbert F |e verfasserin |4 aut | |
700 | 1 | |a Hendriks, Lizza E L |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 390(2024), 4 vom: 25. Jan., Seite 381 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
773 | 1 | 8 | |g volume:390 |g year:2024 |g number:4 |g day:25 |g month:01 |g pages:381 |
856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMc2314327 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 390 |j 2024 |e 4 |b 25 |c 01 |h 381 |